This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).

 Consejos para adolescentes: la realidad sobre el tabaco

This fact sheet for teens provides facts about tobacco. It describes short- and long-term effects, lists signs of use, and helps dispel common myths. It also can be used by prevention professionals, educators, health care providers, and others who come in contact with teens on a regular basis.

Consejos para adolescentes: la realidad sobre los cigarrillos electrónicos

This fact sheet for teens provides facts about vaping. It describes short- and long-term effects and lists signs of vaping. The fact sheet helps to dispel common myths about vaping. Access sources and references cited in this fact sheet.

This fact sheet for teens provides facts about vaping. It describes short- and long-term effects and lists signs of vaping. The fact sheet helps to dispel common myths about vaping. Access sources and references cited in this fact sheet.

This guide explains prescription drug monitoring programs (PDMPs), and how they can enhance clinical decision making. The guide also explains how PDMP improves patient safety, while helping to decrease prescription drug misuse and unintentional overdose deaths.

This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.

This resource explores the lives of five characters living with different substance use disorder conditions. It illustrates the stages of change and the value of treatment, recovery, and motivational incentives. It also includes a change plan worksheet.